1.Body shape and structure characteristics of national women’s handball team athletes
Chinese Journal of Tissue Engineering Research 2013;(37):6689-6694
BACKGROUND:Studies have shown that the physical development potential is often associates with certain combinations of hand print features.
OBJECTIVE:To analyze the body shape and structure characteristics of national women’s handbal team athletes.
METHODS:Fifty national women’s handbal team athletes were col ected from Shanghai, Beijing, Tianjin and Anhui provinces and PLA. The body shapes of the athletes were measured by the Research Institute of National Sports Council, and the hand prints were col ected. The common factors of body shape and structure characteristics were analyzed with factor analysis method, including height, weight, forearm length, wrist circumference, hand length, hand width and index finger length and large-handedness index.
RESULTS AND CONCLUSION:The body shape and structure characteristics of national women’s handbal team athletes could be divided into four types:long trunk lean type indicator, hand skeleton and muscle fiber development level index, flexible quality indicators as wel as the alertness and mental level indicators. The long trunk lean type indicator was the main factor to affect body shape and structure characteristics of national women’s handbal team athletes.
2.Effect of periodontitis on rats with chronic bacterial prostatitis
Chengcheng LIU ; Guangwei HAN ; Jiangchuan CHEN ; Shanhong YI ; Xiaoqian FENG
Journal of Regional Anatomy and Operative Surgery 2015;(1):6-10
Objective To study the effect of periodontitis on rats with chronic bacterial prostatitis. Methods A total of 80 male rats were randomly divided into the 4 weeks group (n=40) and the 8 weeks group (n=40), and then the two groups were randomly divided into the normal control group (N=10), the periodontitis group (PE=10), the chronic bacterial prostatitis group (CBP=10), and the peri-odontitis+chronic bacterial prostatitis group (CBP+PE=10) respectively. The pathological changes, inflammation score, level of TNF-αand IL-1β, and indicators of periodontal of all rats were observed. Results In the 4 weeks group, the indicators of periodontal in PE group and CBP+PE group were higher than that in N group and CBP group (P<0. 05), but there was no significant difference between PE group and CBP+PE group as well as between the N group and the CBP group (P>0. 05). The pathological changes, inflammation score,TNF-αlevel ,IL-1 β level in CBP+PE group and CBP group were higher than that in N group and PE group (P<0. 05), while there was no sing-nificant difference between N group and PE group as well as between CBP+PE group and CBP group (P>0. 05). In the 8 weeks group, the indicators of periodontal in PE group and CBP+PE group were higher than that in N group and CBP group (P<0. 05), but there was no sig-nificant difference between PE group and CBP+PE group as well as between the N group and the CBP group (P>0. 05). The pathological changes, inflammation score, TNF-α level , IL-1 β level in CBP +PE group and CBP group were higher than that in N group and PE group (P<0. 05),while there was no singnificant difference between N group and PE group (P>0. 05). The pathological changes, inflam-mation score,TNF-α level ,IL-1 β level in CBP+PE group were higher than those in the CBP group (P<0. 05). Compared between 4 weeks group and 8 weeks group, there was no obvious difference in N group in terms of periodontal indexes. Periodontal indexes in 8 weeks PE group was higher than that in 4 weeks PE group (P<0. 05), but there was no significant difference prostate tissue pathology, inflamma-tion score,TNF-α level,IL-1βlevel (P>0. 05). Pathology, inflammation score,TNF-αlevel, IL-1βlevel in 8 weeks CBP group were low-er compared to 4 weeks CBP group (P<0. 05), and there was no significant difference between the indexes of periodontal (P>0. 05). Prostate tissue pathology, inflammation score, TNF-αlevel, IL-1βlevel in 8 weeks CBP+PE group were lower than that in 4 weeks CBP+PE group (P<0. 05), but indicators of periodontal in 8 weeks CBP+PE group were higher than 4 weeks CBP+PE group (P<0. 05). Conclusion Chronic bacterial prostatitis combined with periodontitis can inhibit self-healing tendency of chronic bacterial prostatitis of rats and keep rats in chronic inflammatory phase.
3.The common problems and solution of graduate education in cilinical medicine professional degree
Jiangchuan DONG ; Dilong CHEN ; Qing LI ; Yiting CHEN ; Jing WU ; Yahbin HOU
Chinese Journal of Medical Education Research 2011;10(9):1087-1089
With the size of graduate education continues to expand,deepening the reform of graduate education to improve the quality of graduate education has become the core of graduate education.This paper introduces the common problems and solution of graduate education in cilinical medicine professional degree.
4.The analysis of cerebral angiography of the ischemic cerebrovaseular diseases
Dayong DU ; Hang XU ; Dongju ZHANC ; Xi WANG ; Jiangchuan WANG ; Hongmei ZHANG ; Qingjun WANC ; Yuekun WANG ; Shuyuan CHEN
Chinese Journal of Postgraduates of Medicine 2008;31(34):21-24
Objective To study the nlanifestation and the clinical significance of the cerebral angiography of the isehemic cerebrovascular diseases.Methods Digital sublraction angiography(DSA)was taken in 312 patients with cerebral infarction and transient ischemic attack(TLA).The distribution of the lesion in the extra/intracranial arteries was compared.Results Cerebral angiography showed that the stenosis and occlusion was dominant in the intracranial arteries at the cerebral infarction in the internal carotid artery system and vertebrobasilar artery system[59.57%(56/94)and 61.90%(26/42)].TIA of internal carotid artery system was mainly because of stenosis of intracranial arteries (68.75%,22/32).TIA of vertebrobasilar artery system was mainly because of stenosis of extracranial arteries(61.70%,29/47).Conclusions The diseases of the intracranial arteries are the main causes of cerebral infarction(including internal carotid artery system and vertebrobasilar artery system) and TIA of internal carotid artery system. The diseases of the extracranial arteries are main causes of TIA of vertebrobasilar artery system.
5.Analysis of Clinical Trial Institutions in Chongqing Area
Liya CAO ; Linli XIE ; Jiangchuan XIE ; Xinmei PAN ; Pan MA ; Xin ZHANG ; Yongchuan CHEN
Chinese Journal of Modern Applied Pharmacy 2024;41(9):1275-1280
OBJECTIVE
To investigate the current situation of clinical trial institutions in Chongqing after the recording system of clinical trial institutions, and to put forward suggestions.
METHODS
A total of 34 clinical trial institutions in Chongqing were selected as the research objects. The research contents mainly included the basic situation of the institutions, staffing, hardware and software construction, project operation and work difficulties, etc. Combined with the research results, suggestions were put forward for the difficulties of the new and old institutions in the operation of clinical trial institutions.
RESULTS
A total of 29 questionnaires were collected and 29 were valid. The release of clinical trial resources in Chongqing were not sufficient and uniform, there were problems such as insufficient incentive policies, lack of information platform construction, and the number and professional degrees of practitioners need to be improved. The new institutions had certain advantages in project load, office space and willingness to undertake, but it was restricted by principle investigator qualification, project experience and institutional reputation.
CONCLUSION
It is suggested to clarify the incentive mechanism, enhance the enthusiasm of clinical trials and establish a standardized training mechanism for clinical trial professionals. Make full use of the information platform to improve the efficiency of clinical trials, build a regional information platform to share information and resources, and accelerate the development of regional clinical trials.
6.Talking about the Key Points and Notices of Drug Management in Clinical Trials
Jiangchuan XIE ; Wei GUO ; Linli XIE ; Minghong LI ; Xinmei PAN ; Liya CAO ; Yongchuan CHEN
China Pharmacy 2019;30(21):2894-2898
OBJECTIVE: To provide references for improving the standard operating procedures of drug management in clinical trials and drug management in clinical trials. METHODS: According to Good Clinical Practice (GCP), Data On-site Verification Points of Drugs Clinical Trial, Qualification Examination Rules of Drug Clinical Trial Institution, based on the quality control project carried out in our hospital since July 2016, the matters needing attention in the non-standard operation and key process of drug management in clinical trial were summarized, and the improvement measures were discussed. RESULTS & CONCLUSIONS: Non-standard drug management is a high-incidence link of non-standard operation in the trial process. Among them, the acceptance, distribution and use of drugs are the three links with the highest incidence of non-standard operation of drug management in the trial process. Therefore, when formulating the relevant management system, each institution should pay attention to it according to its own situation; such as, when accepting drugs in clinical trials, attention should be paid to checking the intact degree of drug packaging; drugs transported in cold chain should also be checked for temperature records and rejected in case of over-temperature; the copies of the waybill should be kept in file with the original to avoid fading of the thermosensitive paper; whether the relevant characteristics of the control drugs and placebos meet the requirements. Institutions can standardize the key links of drug management in the trial process, the time of project establishment, project start-up, quality control and supervision, formulate and constantly improve the relevant drug management system and standard operating procedures (SOP). For example, when starting a project, attention should be paid to the participation of drug administrators in the training and signature of start-up meeting, whether the design of the form is complete, standardized and operable. It is necessary for clinical trial institutions to pay attention to the standardization and precision of drug management and the key links in clinical trials.
7.Common protocol deviations and improvement methods and precautions in drug clinical trials
Jiangchuan XIE ; Linli XIE ; Liya CAO ; Xinmei PAN ; Pan MA ; Yongchuan CHEN
China Pharmacy 2022;33(13):1554-1558
OBJECTIVE To learn the common proto col deviation (PD)in the process of drug clinical trials and discuss the methods and precautions for preventing and reducing PD so as to provide reference for the standardization of drug clinical trials. METHODS According to Good Clinical Practice ,Notice on Issuing Guidelines for Planning and Reporting of Data Management and Statistical Analysis of Drug Clinical Trials ,Guidelines for Ethical Review of Drug Clinical Trials ,ICH E 3,ICH E 6(R2)and other regulations ,the PD reported in the relevant projects managed by the author from March 2017 to February 2022,as well as the PD found in the submission materials and project quality control ,were sorted out and statistically analyzed. RESULTS & CONCLUSIONS A total of 39 drug clinical trials were included ,and 212 subjects were selected. In all projects ,258 PDs were reported,including 28 major PD (accounting for 10.85%)and 230 ordinary PD (accounting for 89.15%). The report of PD mainly included missed inspections/tests (93 reports,accounting for 36.05%),lack of visits (36 reports,accounting for 13.95%), inspection/testing out-of-window (29 reports,accounting for 11.24%),dosage and usage of test drugs (28 reports,accounting for 10.85%),drug over-temperature/missing temperature (21 reports,accounting for 8.14%),etc. Avoiding and reducing the occurrence of PD requires the efforts of multiple parties :the sponsor designs a reasonable protocol with appropriate interview rate and window period after listening to the opinions of multiple parties ;the investigators and clinical research coordinator should strengthen their own learning and training ,and be familiar with the protocol ,Good Clinical Practice and corresponding regulations;the compliance education of the subjects should be strengthened ;the institutional offices and ethics committees should conduct multi-angle and whole-process supervision and management when a drug clinical trial is approved ,in progress ,and jsyj- concluded,to ensure the safety rights and interests of the zdcxX0079) subjects and the quality of clinical trials. On this basis ,all parties should communicate effectively and timely ,report PD in time ,and conduct special studies on major PD that have com occurred and key links that are prone to PD.
8.Common problems and suggestions of biological sample management in drug clinical trials
Jiangchuan XIE ; Linli XIE ; Pan MA ; Xinmei PAN ; Liya CAO ; Xin ZHANG ; Yongchuan CHEN
China Pharmacy 2024;35(5):524-528
OBJECTIVE To provide a reference for improving the relevant standard operating procedures (SOP) and biological sample management in drug clinical trials. METHODS According to Good Clinical Practice, Data On-site Verification Points of Drugs Clinical Trials, Human Genetic Resources Management Regulations Implementation Rules, Qualification Examination Rules of Drug Clinical Trials Institution, based on the experience of managing clinical trials programs, the irregularities in biological samples management were analyzed by using statistical quality control tables and protocol deviation (PD) reported by sponsors, in the context of the quality control of drug clinical trials projects managed by the author from July 2016 to May 2023. The precautions in various aspects of sample management were put forward. RESULTS & CONCLUSIONS A total of 101 biospecimen- related irregularities were found in the 60 drug clinical trials projects. Biological sample collection, preservation, and handling were the aspects with the highest incidence of irregular operations in biological sample management, accounting for 37.62%, 25.74%, and 21.78%, respectively. Regulating the management of biospecimens requires multiple efforts. The institutional office and the ethics committee carefully reviewed the consistency of the protocols, informed consent, and genetic office application involving biospecimen collection and handling when the project was initiated. Institutional office quality controllers should pay attention to the attendance and training of authorized personnel at project initiation. The principal investigator, research nurse, collector, handler, transporter, relevant personnel of the central laboratory, and institutional office quality controller have their roles during the project implementation phase. On this basis, all parties involved in the management of biological samples should do a good job of effective communication, find problems and report them in time, and conduct special studies on key aspects.